U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone954-835-1500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.70 million
Profitability
Miscellaneous
Employees10
Next Earnings Date3/11/2020 (Estimated)
OptionableNot Optionable
US Stem Cell (OTCMKTS:USRM) Frequently Asked Questions
What is US Stem Cell's stock symbol?
US Stem Cell trades on the OTCMKTS under the ticker symbol "USRM."
How were US Stem Cell's earnings last quarter?
US Stem Cell Inc (OTCMKTS:USRM) posted its quarterly earnings results on Wednesday, August, 7th. The company reported $0.00 earnings per share for the quarter. The firm earned $1.30 million during the quarter. View US Stem Cell's Earnings History.
When is US Stem Cell's next earnings date?
Has US Stem Cell been receiving favorable news coverage?
News articles about USRM stock have trended positive recently, InfoTrie reports. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. US Stem Cell earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for US Stem Cell.
Who are some of US Stem Cell's key competitors?
What other stocks do shareholders of US Stem Cell own?
Who are US Stem Cell's key executives?
US Stem Cell's management team includes the folowing people:
- Mr. Michael Tomas, CEO, Pres, CFO & Director (Age 53)
- Dr. Kristin C. Comella Ph.D., Chief Science Officer & Director (Age 42)
- Dr. Colleen Robb, Sr. Compliance Officer
- Mr. Phil Posa, Sr. VP of U.S. & International Sales
- Ms. Evelyn Flores, Corp. Controller
How do I buy shares of US Stem Cell?
Shares of USRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is US Stem Cell's stock price today?
One share of USRM stock can currently be purchased for approximately $0.00.
How big of a company is US Stem Cell?
What is US Stem Cell's official website?
How can I contact US Stem Cell?
US Stem Cell's mailing address is 1560 SAWGRASS CORPORATE PKWY 4TH FLOOR, SUNRISE FL, 33325. The company can be reached via phone at 954-835-1500 or via email at [email protected]
MarketBeat Community Rating for US Stem Cell (OTCMKTS USRM)
MarketBeat's community ratings are surveys of what our community members think about US Stem Cell and other stocks. Vote "Outperform" if you believe USRM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe USRM will underperform the S&P 500 over the long term. You may vote once every thirty days.
